After hosting a call with a foot and ankle orthopedic surgeon who was the first in the Midwest to perform the Cartiva procedure, Piper Jaffray analyst Matt O'Brien recommends investors start or build positions in Wright Medical at current share levels. The analyst believes the Cartiva acquisition will represent a "solid double or triple" for the company. Cartiva is a "highly differentiated product that will provide a beachhead in competitive accounts," and growth prospects will likely benefit from the scale of the Wright Medical lower extremity sales force driving upside to revenue expectations, O'Brien tells investors in a research note. He reiterates an Overweight rating on the shares with a $32 price target.